United States Diabetes Care Drugs and Devices Market Size, Share, and Forecast 2025-33

United States Diabetes Care Drugs and Devices Market Overview

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 5.63% (2025-2033)

The diabetes care industry in the U.S. is growing steadily. This growth is due to better treatment options and greater health awareness. Enhancements in drugs and devices have also improved patient care and management. According to the latest report by IMARC Group, the United States diabetes care drugs and devices market size was valued at USD 54.84 billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 89.76 billion by 2033, exhibiting a CAGR of 5.63% from 2025-2033

Download sample copy of the Report: https://www.imarcgroup.com/united-states-diabetes-care-drugs-devices-market/requestsample

United States Diabetes Care Drugs and Devices Industry Trends and Drivers:

The US diabetes care market is changing fast. This change has happened because more people have diabetes. New technology also helps meet their needs. This market will likely see new drug therapies. GLP-1 receptor agonists and SGLT2 inhibitors will help with better blood sugar control. They also aid in weight loss and lower the risk of heart problems. These are effective therapies stimulating a growing interest in personalized medicine. Biosimilars are changing the pricing game. This helps provide better treatments for many people. Focusing on combination therapy with different action mechanisms changes our treatment approach. It offers a wider range of options for treating patients. They provide real-time data and precise dosing, which helps patients perform better. Here are some trends boosting growth in the diabetes care drug market. Pharmaceutical companies are investing heavily in research and development. They aim to create next-generation therapies to meet unmet needs.

The United States diabetes care market is seeing fast changes. This is mainly due to new devices for glucose monitoring and insulin delivery. Real-time figures cut down on fingerstick tests. They also help patients stick to their therapy. By providing glucose level information instantly, they boost patient compliance. Also, connecting CGM systems to smartphones and cloud platforms makes them more appealing. Now, quick data sharing with healthcare providers and caregivers is possible. Insulin pumps with automated insulin delivery (AID) are becoming more popular. They mimic how a healthy pancreas works. This allows for more precise insulin dosing. These devices are highly effective for glycemic control and hypoglycemia risk. This would be mainly relevant for type 1 patients. It has changed diabetes care with new wearables and AI tools. These technologies offer predictive insights and tailored treatment plans. Patients will likely take on a bigger role in managing their diseases as new tools emerge.

United States Diabetes Care Drugs and Devices Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest United States diabetes care drugs and devices market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.

The report has segmented the market into the following categories:

Analysis by Offering:

  • Devices
    • Monitoring Devices
      • Self-monitoring Blood Glucose Devices
      • Continuous Blood Glucose Monitoring
    • Management Devices
      • Insulin Pump
      • Insulin Syringes
      • Insulin Cartridges
      • Disposable Pens
  • Drugs
    • Oral Anti-Diabetes Drugs
    • Insulin Drugs
    • Combination Drugs
    • Non-Insulin Injectable Drugs

Analysis by Distribution Channel:

  • Online
  • Offline

Regional Analysis:

  • Northeast
  • Midwest
  • South
  • West

Competitive Landscape:

The competitive landscape of the industry has also been examined, along with the profiles of the key players.

  • Astrazeneca
  • Eli Lilly
  • Sanofi
  • Boehringer Ingelheim
  • Novo Nordisk
  • Becton and Dickinson
  • Medtronic
  • Abbott
  • Johnson & Johnson
  • Insulet Corporation
  • Dexcom

Key highlights of the Report:

  • Market Performance (2019-2024)
  • Market Outlook (2025-2033)
  • COVID-19 Impact on the Market
  • Porter’s Five Forces Analysis
  • Strategic Recommendations
  • Historical, Current, and Future Market Trends
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Structure of the Market
  • Value Chain Analysis
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145